date:Dec 10, 2012
nsequence of this transaction, Evolva is reprioritising activities on its existing pipeline.
Evolva will focus internal resources on:
High value ingredients deriving from the phenylpropanoid pathway, notably resveratrol and vanillin, with additional products expected to reach market from 2016 onwards;
High value ingredients deriving from the isoprenoid pathway, notably stevia and saffron, with additional products expected to reach market after 2016.
Activities on other pathways will continu